skip to content


PureTech wins US patent for speech analysis technology

20 September 2017 09:33

Biopharmaceutical company PureTech Health (PRTC) announced the award of a US patent for speech analysis technology.

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,763,617 for PureTech's Sonde vocal biomarkers programme. The patent broadly covers methods of assessing a mental or physical condition of a subject, using phonetic structures, or phones, extracted from speech audio waveforms. The issued patent is exclusively licensed under an agreement with the Massachusetts Institute of Technology (MIT) and provides coverage through at least 2032. "This newly issued patent represents, to the best of our knowledge, the only coverage for novel vocal biomarkers that have been demonstrated to enhance vocal analysis performance for assessment of a broad range of diseases," said Jim Harper, PhD, PureTech Health Vocal Biomarker Programme Lead. "Issuance of this patent strengthens our leading intellectual property portfolio in the emerging field of acoustic voice analysis for health, and it provides validation of our novel vocal biomarkers technology for the assessment of mental and physical conditions."

At 9:30am: (LON:PRTC) PureTech Health Plc share price was +1.5p at 136p

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.